That is the case of toll-like receptor agonists, such as dextran-conjugated CpG oligodeoxynucleotides (71) and double-stranded RNAs (72, 73), whose application in vaccine formulations enhances tumor-specific TH1-polarized CD4+ T cells and CTL responses. Here, CD4 is linked to neoplasm.